US Patent

US11020448 — Methods comprising desmopressin

Method of Use · Assigned to Ferring BV · Expires 2029-05-21 · 3y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of reducing nocturnal voids by administering desmopressin over a minimum treatment period.

USPTO Abstract

The present disclosure is directed to reducing nocturnal voids by administering a dose of desmopressin over a minimum treatment period compared to before administration, and maintaining or improving the reduction of nocturnal voids over the minimum treatment period.

Drugs covered by this patent

desmopressin-acetate (DESMOPRESSIN ACETATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2327`	—	desmopressin-acetate

Patent Metadata

Patent number: US11020448
Jurisdiction: US
Classification: Method of Use
Expires: 2029-05-21
Drug substance claim: No
Drug product claim: No
Assignee: Ferring BV
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.